• HOME>
  • Investor Relations>
  • IR News>
  • Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for Alzheimer's Disease Treatment ”Donepezil hydrochloride tablets/OD tablets 3mg/5mg [DSP]”.

IR News

Jul. 19, 2011Print(PDF/103KB)Products

Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for Alzheimer's Disease Treatment ”Donepezil hydrochloride tablets/OD tablets 3mg/5mg [DSP]”.

Dainippon Sumitomo Pharma Co., Ltd. (DSP) (Headquarters: Osaka, Japan; President: Masayo Tada) announces that as part of a plan to strengthen the lineup in the CNS area, DSP is handling a generic drug in the area concerned. As of July 15, 2011, DSP has obtained manufacturing and marketing approval for the Alzheimer's disease treatment "Donepezil hydrochloride tablets/OD tablets 3mg/5mg [DSP]" in Japan from the Ministry of Health, Labour and Welfare. These four products are scheduled to be launched after NHI price listing.

In domestic pharmaceuticals, DSP designates the Central Nervous System field as one of its focus marketing areas, and offers various treatments such as atypical antipsychotics "LONASEN®" and "LULLAN®", Parkinson's disease drug "TREREIF®", norepinephrine-activating neural function ameliorant "DOPS®", anti-epileptic drug "EXCEGRAN®", and serotonin-agonist antianxiety drug "SEDIEL®". Approximately 200 CNS MRs in the CNS Sales & Marketing Division newly established in April 2011 are developing activities to provide information on these products. On June 24, 2011, DSP created "Establish Groups" dedicated to generic drugs in the CNS area under CNS Sales and Marketing, each under the CNS Higashi-Nippon Region, CNS Capital Region, CNS Kinki-Tokai Region and CNS Nishi-Nippon Regions with the aim to promote sales of generic drugs in the CNS area.

In the future, DSP will positively invest in products to contribute to the treatment of CNS disorders regardless of whether they are new or generic drugs.

Attached reference: Profile of "Donepezil hydrochloride tablets/OD tablets 3mg/5mg [DSP]"

(Reference)

Profile of "Donepezil hydrochloride tablets/OD tablets 3mg/5mg [DSP] "
[Product Name] Donepezil hydrochloride tablets 3mg [DSP]
Donepezil hydrochloride tablets 5mg [DSP]
Donepezil hydrochloride OD tablets 3mg [DSP]
Donepezil hydrochloride OD tablets 5mg [DSP]
[Generic Name] Donepezil hydrochloride
[Content / Description] Donepezil hydrochloride tablets 3mg/5mg [DSP]: film-coated tablets containing 3mg or 5mg of donepezil hydrochloride.
Donepezil hydrochloride OD tablets 3mg/5mg [DSP]: orally disintegrating tablets containing 3mg or 5mg of donepezil hydrochloride.
[Indication] Suppression of the progression of dementia symptoms in mild to moderate Alzheimer-type dementia.
[Dose and Administration] The usual initial adult dose for oral use is 3 mg of donepezil hydrochloride once daily. After 1 to 2 weeks the dosage is increased to 5 mg.
[Manufacturer and Distributor] Dainippon Sumitomo Pharma Co., Ltd.